LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an ...

Shionogi & Co. shares fell sharply Thursday morning after a Japanese government panel rejected granting emergency approval for the company’s Covid-19 drug. The company’s shares were recently 8 ...

However, this allows Shionogi to be the next great COVID opportunity, offering both significant profit generation for shareholder benefit and undervaluation. So far, Xocova has already allowed for ...

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict Here's a roundup of top developments ...

Shionogi & Co.’s experimental Covid-19 treatment Xocova failed to win the backing of health experts in Japan who said there wasn’t enough data to show the medicine’s efficacy. The panel ...

Shionogi has been awarded $375m by the US Department of Health and Human Services (HHS) to develop a long-acting therapeutic aimed at protecting vulnerable populations from Covid-19. The funding ...

Earnings Estimate Revisions for Shionogi & Co. This company is expected to earn $0.27 per share for the fiscal year ending March 2025, which represents a year-over-year change of -58.5%.

Japan has approved the Shionogi's antiviral therapy, Xocova, for COVID-19 on an emergency basis. The government has also purchased 1 million doses initially, estimated to be worth $2.5 billion USD.

TOKYO, Feb 27 (Reuters) - Japan's Shionogi & Co Ltd (4507.T), opens new tab believes its COVID-19 pill will easily garner $2 billion in annual sales if it secures U.S. approval, which the company ...